Physician profile
Suntharo Ly
NPI 1134208168
$16,381.99
in general payments reported to CMS, 2019-2025
40 companies · $923 in 2025
The $923 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,774 · 2020: $792 · 2021: $1,121 · 2022: $888 · 2023: $2,820 · 2024: $8,063 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $8,053 · Food and Beverage: $3,754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $8,053.25 |
| Food and Beverage | $3,753.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $8,695.95 | 2021-2024 | Hawkone, Micra, Abre |
| Novartis Pharmaceuticals Corporation | $766.76 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $734.11 | 2019-2025 | Lifevest |
| Heartflow, INC. | $717.39 | 2019-2025 | Ffrct |
| Janssen Pharmaceuticals, INC | $577.35 | 2019-2024 | Xarelto |
| Abbott Laboratories | $527.19 | 2019-2025 | Ensite, Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Boston Scientific Corporation | $512.31 | 2019-2025 | Watchman Flx, Watchman Access System, Lux-Dx Insertable Cardiac Monitor |
| Astrazeneca Pharmaceuticals Lp | $476.98 | 2019-2025 | Lokelma, Farxiga, Brilinta |
| Merck Sharp & Dohme LLC | $399.22 | 2021-2024 | Verquvo |
| Bardy Diagnostics, INC. | $295.00 | 2019-2021 | |
| Abiomed | $285.64 | 2019-2024 | Impella |
| Astellas Pharma US INC | $280.73 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.10 | 2019-2025 | Jardiance |
| Atricure, INC. | $230.56 | 2023-2024 | |
| Pfizer INC. | $209.91 | 2019-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suntharo Ly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.